ClinicalTrials.gg

Program

AK157D1 for injection

Its studies are led by Akeso.

Furthest: phase 1, since Sep 21, 20261 company-led study, 1 open or runningNext primary completion: Mar 30, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akeso11 open or runningphase 1since Sep 21, 2026Sep 21, 2026Mar 30, 2029phase 1 · NCT07847281

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 21, 2026First study: phase 1 study in Advanced Solid TumorsFirst studyNCT07847281 · 243 planned · China

Ahead

  1. Mar 30, 2029Primary completion: phase 1 study in Advanced Solid TumorsNCT07847281

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07847281Advanced Solid Tumors · China1RecruitingMar 30, 2029243

How it is read

Names in the registry

  • “AK157D1 for injection”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.